Chronic sialorrhea market seen reaching $1.02 billion by 2030
The chronic sialorrhea market is projected to grow from $0.76 billion in 2025 to $0.81 billion in 2026, then reach $1.02 billion by 2030, according to The Business Research Company. Growth is being driven by rising neurological disease rates, expanding treatment options and greater research investment across key regions.
Why it matters: - Chronic sialorrhea is tied to neurological conditions such as Parkinson’s disease, cerebral palsy and ALS, so market growth tracks a larger patient-care need. - Expanded treatment options can reduce complications like aspiration and improve oral function and quality of life for patients. - The market’s growth points to rising demand for specialty care, injectable therapies and assistive oral devices.
What happened: - The Business Research Company’s Chronic Sialorrhea Global Market Report 2026 projects the market will rise from $0.76 billion in 2025 to $0.81 billion in 2026. - The report forecasts the market will reach $1.02 billion by 2030. - The report says North America held the largest market share in 2025. - The report says Asia-Pacific is expected to post the fastest growth during the forecast period.
The details: - The market is projected to grow at a 6.2% CAGR from 2025 to 2026. - The report projects a 6.0% CAGR through 2030. - Historical growth has been driven by higher incidence of neurological disorders, broader use of anticholinergic drugs, expansion of rehabilitation services, better diagnostics for salivary conditions and more specialty clinic offerings. - Future growth is expected to come from approval of new injectable therapies, stronger demand for home care solutions, expansion in assistive oral devices, an aging population and more investment in neurological disease management. - Key trends include greater adoption of botulinum toxin treatments, increased use of non-invasive therapies, more neurology-focused sialorrhea care, growth in assistive medical devices and a stronger focus on patient quality of life. - Chronic sialorrhea is defined as persistent overproduction or poor control of saliva. - Treatment typically includes pharmacological options, botulinum toxin injections or surgery. - The main treatment goals are improved oral function, fewer complications and better patient well-being. - The report covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa in addition to North America and Asia-Pacific. - The report includes new analytical features such as market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, and updated graphics and tables. - The report offers a free sample and a full report online at the company’s sample request page and the full market report.
Between the lines: - The market outlook suggests chronic sialorrhea is moving from a niche condition into a more structured specialty-care category. - R&D spending is a visible growth catalyst because new therapies and diagnostics can broaden diagnosis and improve treatment uptake. - The report links market expansion to broader demographic and disease trends, especially aging and neurodegenerative disorders. - The UK government increased net R&D spending to £17.4 billion ($22.1 billion) in 2023 from £16.1 billion ($20.45 billion) in 2022, according to the Office for National Statistics. - Parkinson’s UK said in September 2023 that about 153,000 people in the UK live with Parkinson’s disease, with that figure expected to rise to about 172,000 by 2030.
What's next: - The market is expected to keep expanding as injectable therapies, home care solutions and assistive devices gain broader use. - Demand should continue rising as aging populations and neurodegenerative disease prevalence increase the number of patients needing sialorrhea management. - The report suggests Asia-Pacific could become a more important growth market over the forecast period.
The bottom line: - Chronic sialorrhea is emerging as a small but steadily expanding healthcare market, with treatment innovation and neurodegenerative disease prevalence shaping the next phase of growth.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Healthy Living Europe
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.